메뉴 건너뛰기




Volumn 13, Issue SUPPL.1, 2013, Pages

New insights, recent advances, and current challenges in the biological treatment of multiple myeloma

Author keywords

Bone marrow milieu; Carfilzomib; Genetic alterations; Multiple myeloma; Pomalidomide

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLIN D1; CYCLIN D3; CYCLOPHOSPHAMIDE; DARATUMUMAB; DELANZOMIB; DEXAMETHASONE; ELOTUZUMAB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IXAZOMIB; LENALIDOMIDE; OPROZOMIB; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; THALIDOMIDE; VEMURAFENIB; VORINOSTAT;

EID: 84879571938     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.807337     Document Type: Review
Times cited : (8)

References (169)
  • 2
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
    • (2008) Blood , vol.111 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 3
  • 4
    • 84863919927 scopus 로고    scopus 로고
    • Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    • Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953-9
    • (2012) J Clin Oncol , vol.30 , pp. 1953-1959
    • Lonial, S.1    Vij, R.2    Harousseau, J.L.3
  • 5
    • 36148961606 scopus 로고    scopus 로고
    • Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
    • Gonzalez D, van der Burg M, Garcia-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112-21
    • (2007) Blood , vol.110 , pp. 3112-3121
    • Gonzalez, D.1    Van Der Burg, M.2    Garcia-Sanz, R.3
  • 6
    • 0037103287 scopus 로고    scopus 로고
    • Genomic abnormalities in monoclonal gammopathy of undetermined significance
    • Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100:1417-24
    • (2002) Blood , vol.100 , pp. 1417-1424
    • Fonseca, R.1    Bailey, R.J.2    Ahmann, G.J.3
  • 7
    • 8844266049 scopus 로고    scopus 로고
    • Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
    • Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004;18:1879-82
    • (2004) Leukemia , vol.18 , pp. 1879-1882
    • Kaufmann, H.1    Ackermann, J.2    Baldia, C.3
  • 8
    • 11144235574 scopus 로고    scopus 로고
    • Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors
    • Rasmussen T, Kuehl M, Lodahl M, et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317-23
    • (2005) Blood , vol.105 , pp. 317-323
    • Rasmussen, T.1    Kuehl, M.2    Lodahl, M.3
  • 9
    • 0035892119 scopus 로고    scopus 로고
    • Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
    • Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-6
    • (2001) Blood , vol.98 , pp. 3082-3086
    • Avet-Loiseau, H.1    Gerson, F.2    Magrangeas, F.3
  • 10
    • 67650745974 scopus 로고    scopus 로고
    • Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: Sequential analysis of a single case
    • Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94:1024-8
    • (2009) Haematologica , vol.94 , pp. 1024-1028
    • Chiecchio, L.1    Dagrada, G.P.2    Protheroe, R.K.3
  • 11
    • 79956039754 scopus 로고    scopus 로고
    • Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
    • Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700
    • (2011) Blood , vol.117 , pp. 4696-4700
    • Munshi, N.C.1    Anderson, K.C.2    Bergsagel, P.L.3
  • 12
    • 78049501226 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    • Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4
    • (2010) J Clin Oncol , vol.28 , pp. 4630-4634
    • Avet-Loiseau, H.1    Leleu, X.2    Roussel, M.3
  • 13
    • 79955492575 scopus 로고    scopus 로고
    • Chromosomal aberrations +1q21 and del (17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
    • Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations +1q21 and del (17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011;117:2136-44
    • (2011) Cancer , vol.117 , pp. 2136-2144
    • Klein, U.1    Jauch, A.2    Hielscher, T.3
  • 14
    • 84856706335 scopus 로고    scopus 로고
    • A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial
    • Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-55
    • (2012) Leukemia , vol.26 , pp. 349-355
    • Boyd, K.D.1    Ross, F.M.2    Chiecchio, L.3
  • 15
    • 84860907057 scopus 로고    scopus 로고
    • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    • Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82
    • (2012) Blood , vol.119 , pp. 4375-4382
    • Kumar, S.1    Flinn, I.2    Richardson, P.G.3
  • 16
    • 84872460585 scopus 로고    scopus 로고
    • Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
    • Ludwig H, Viterbo L, Greil R, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2013;31:247-55
    • (2013) J Clin Oncol , vol.31 , pp. 247-255
    • Ludwig, H.1    Viterbo, L.2    Greil, R.3
  • 17
    • 74949119502 scopus 로고    scopus 로고
    • Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM)
    • Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-7
    • (2010) Blood , vol.115 , pp. 32-37
    • Roussel, M.1    Moreau, P.2    Huynh, A.3
  • 18
    • 84862804479 scopus 로고    scopus 로고
    • Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
    • Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012;157:553-63
    • (2012) Br J Haematol , vol.157 , pp. 553-563
    • Nishihori, T.1    Alekshun, T.J.2    Shain, K.3
  • 19
    • 84860709392 scopus 로고    scopus 로고
    • Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
    • Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-91
    • (2012) N Engl J Med , vol.366 , pp. 1782-1791
    • Attal, M.1    Lauwers-Cances, V.2    Marit, G.3
  • 20
    • 84866851061 scopus 로고    scopus 로고
    • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
    • Mateos MV, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012;120:2581-8
    • (2012) Blood , vol.120 , pp. 2581-2588
    • Mateos, M.V.1    Oriol, A.2    Martinez-Lopez, J.3
  • 21
    • 84865171981 scopus 로고    scopus 로고
    • Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial
    • Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-55
    • (2012) J Clin Oncol , vol.30 , pp. 2946-2955
    • Sonneveld, P.1    Schmidt-Wolf, I.G.2    Van Der Holt, B.3
  • 22
    • 84870760136 scopus 로고    scopus 로고
    • Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM)
    • abstract 8100
    • Kaufman J, Nooka A, Muppidi S, et al. Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM). J Clin Oncol 2012;30:abstract 8100
    • (2012) J Clin Oncol , vol.30
    • Kaufman, J.1    Nooka, A.2    Muppidi, S.3
  • 23
    • 84855917055 scopus 로고    scopus 로고
    • Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma
    • Corso A, Galli M, Mangiacavalli S, et al. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. Am J Hematol 2012;87:150-4
    • (2012) Am J Hematol , vol.87 , pp. 150-154
    • Corso, A.1    Galli, M.2    Mangiacavalli, S.3
  • 24
    • 54249092519 scopus 로고    scopus 로고
    • Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myelome
    • Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008;26:4798-805
    • (2008) J Clin Oncol , vol.26 , pp. 4798-4805
    • Decaux, O.1    Lode, L.2    Magrangeas, F.3
  • 25
    • 33947217497 scopus 로고    scopus 로고
    • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    • Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84
    • (2007) Blood , vol.109 , pp. 2276-2284
    • Shaughnessy Jr., J.D.1    Zhan, F.2    Burington, B.E.3
  • 26
    • 84869085660 scopus 로고    scopus 로고
    • A gene expression signature for high-risk multiple myeloma
    • Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012;26:2406-13
    • (2012) Leukemia , vol.26 , pp. 2406-2413
    • Kuiper, R.1    Broyl, A.2    De Knegt, Y.3
  • 27
    • 34147129816 scopus 로고    scopus 로고
    • Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    • Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88
    • (2007) Blood , vol.109 , pp. 3177-3188
    • Mulligan, G.1    Mitsiades, C.2    Bryant, B.3
  • 28
    • 80054840882 scopus 로고    scopus 로고
    • Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
    • Kumar SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011;118:4359-62
    • (2011) Blood , vol.118 , pp. 4359-4362
    • Kumar, S.K.1    Uno, H.2    Jacobus, S.J.3
  • 30
    • 79951494668 scopus 로고    scopus 로고
    • Initial genome sequencing and analysis of multiple myeloma
    • Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72
    • (2011) Nature , vol.471 , pp. 467-472
    • Chapman, M.A.1    Lawrence, M.S.2    Keats, J.J.3
  • 31
    • 80052955256 scopus 로고    scopus 로고
    • BET bromodomain inhibition as a therapeutic strategy to target c-Myc
    • Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17
    • (2011) Cell , vol.146 , pp. 904-917
    • Delmore, J.E.1    Issa, G.C.2    Lemieux, M.E.3
  • 32
    • 9144220841 scopus 로고    scopus 로고
    • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
    • Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101:540-5
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 540-545
    • Mitsiades, C.S.1    Mitsiades, N.S.2    McMullan, C.J.3
  • 33
    • 78650978001 scopus 로고    scopus 로고
    • The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
    • Martinez-Garcia E, Popovic R, Min DJ, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011;117:211-20
    • (2011) Blood , vol.117 , pp. 211-220
    • Martinez-Garcia, E.1    Popovic, R.2    Min, D.J.3
  • 34
    • 20844435806 scopus 로고    scopus 로고
    • Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
    • Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102:8567-72
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 8567-8572
    • Hideshima, T.1    Bradner, J.E.2    Wong, J.3
  • 35
    • 84858640254 scopus 로고    scopus 로고
    • Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    • Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-89
    • (2012) Blood , vol.119 , pp. 2579-2589
    • Santo, L.1    Hideshima, T.2    Kung, A.L.3
  • 36
    • 84878519362 scopus 로고    scopus 로고
    • Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
    • [Epub ahead of print]
    • Richardson PG, Mitsiades CS, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013; [Epub ahead of print]
    • (2013) Leuk Res
    • Richardson, P.G.1    Mitsiades, C.S.2    Laubach, J.P.3
  • 37
    • 76649088636 scopus 로고    scopus 로고
    • Alternative splicing and biological heterogeneity in prostate cancer
    • Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009;6:454-60
    • (2009) Nat Rev Urol , vol.6 , pp. 454-460
    • Rajan, P.1    Elliott, D.J.2    Robson, C.N.3    Leung, H.Y.4
  • 38
    • 79952714413 scopus 로고    scopus 로고
    • Alternate splicing is a frequent event and impacts clinical outcome in myeloma: A high-density exon array analysis of uniformly treated newly-diagnosed myeloma patients
    • abstract 498
    • Munshi N, Li C, Minvielle S, et al. Alternate splicing is a frequent event and impacts clinical outcome in myeloma: a high-density exon array analysis of uniformly treated newly-diagnosed myeloma patients. Blood 2008;112:abstract 498
    • (2008) Blood , vol.112
    • Munshi, N.1    Li, C.2    Minvielle, S.3
  • 39
    • 84864561961 scopus 로고    scopus 로고
    • Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    • Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060-6
    • (2012) Blood , vol.120 , pp. 1060-1066
    • Egan, J.B.1    Shi, C.X.2    Tembe, W.3
  • 40
    • 84861532638 scopus 로고    scopus 로고
    • Clonal competition with alternating dominance in multiple myeloma
    • Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-76
    • (2012) Blood , vol.120 , pp. 1067-1076
    • Keats, J.J.1    Chesi, M.2    Egan, J.B.3
  • 41
    • 84873565928 scopus 로고    scopus 로고
    • Minor clone provides a reservoir for relapse in multiple myeloma
    • Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2012;27(2):473-81
    • (2012) Leukemia , vol.27 , Issue.2 , pp. 473-481
    • Magrangeas, F.1    Avet-Loiseau, H.2    Gouraud, W.3
  • 42
    • 84867051939 scopus 로고    scopus 로고
    • Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
    • Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-20
    • (2012) Nature , vol.490 , pp. 116-120
    • Schmitz, R.1    Young, R.M.2    Ceribelli, M.3
  • 43
    • 84864285223 scopus 로고    scopus 로고
    • RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
    • Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510-13
    • (2012) Nature , vol.487 , pp. 510-513
    • Yu, M.1    Ting, D.T.2    Stott, S.L.3
  • 44
    • 0035195019 scopus 로고    scopus 로고
    • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
    • Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-61
    • (2001) Leukemia , vol.15 , pp. 1950-1961
    • Gupta, D.1    Treon, S.P.2    Shima, Y.3
  • 45
    • 4944230728 scopus 로고    scopus 로고
    • Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion
    • Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91
    • (2004) Blood , vol.104 , pp. 2484-2491
    • Abe, M.1    Hiura, K.2    Wilde, J.3
  • 46
    • 13544255403 scopus 로고    scopus 로고
    • The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications
    • Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95
    • (2005) Blood , vol.105 , pp. 1383-1395
    • Podar, K.1    Anderson, K.C.2
  • 47
    • 84866856496 scopus 로고    scopus 로고
    • Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells
    • Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 2012;120:2620-30
    • (2012) Blood , vol.120 , pp. 2620-2630
    • Bruns, I.1    Cadeddu, R.P.2    Brueckmann, I.3
  • 48
    • 0037179847 scopus 로고    scopus 로고
    • Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma
    • Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-97
    • (2002) Oncogene , vol.21 , pp. 6587-6597
    • Pene, F.1    Claessens, Y.E.2    Muller, O.3
  • 50
    • 0346363760 scopus 로고    scopus 로고
    • The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
    • Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
    • (2003) N Engl J Med , vol.349 , pp. 2483-2494
    • Tian, E.1    Zhan, F.2    Walker, R.3
  • 51
    • 36649035044 scopus 로고    scopus 로고
    • Treatment strategies for bone disease
    • Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplant 2007;40:1139-46
    • (2007) Bone Marrow Transplant , vol.40 , pp. 1139-1146
    • Roodman, G.D.1
  • 52
    • 0033611467 scopus 로고    scopus 로고
    • OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    • Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23
    • (1999) Nature , vol.397 , pp. 315-323
    • Kong, Y.Y.1    Yoshida, H.2    Sarosi, I.3
  • 53
    • 0037930017 scopus 로고    scopus 로고
    • Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/-mice by RANKL transgene
    • Enomoto H, Shiojiri S, Hoshi K, et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/-mice by RANKL transgene. J Biol Chem 2003;278:23971-7
    • (2003) J Biol Chem , vol.278 , pp. 23971-23977
    • Enomoto, H.1    Shiojiri, S.2    Hoshi, K.3
  • 54
    • 0037443533 scopus 로고    scopus 로고
    • RANK ligand and osteoprotegerin in myeloma bone disease
    • Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-8
    • (2003) Blood , vol.101 , pp. 2094-2098
    • Sezer, O.1    Heider, U.2    Zavrski, I.3
  • 55
    • 1542313900 scopus 로고    scopus 로고
    • IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
    • Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004;103:2308-15
    • (2004) Blood , vol.103 , pp. 2308-2315
    • Lee, J.W.1    Chung, H.Y.2    Ehrlich, L.A.3
  • 56
    • 23744507989 scopus 로고    scopus 로고
    • IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
    • Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005;106:1407-14
    • (2005) Blood , vol.106 , pp. 1407-1414
    • Ehrlich, L.A.1    Chung, H.Y.2    Ghobrial, I.3
  • 57
    • 0035664488 scopus 로고    scopus 로고
    • Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease
    • Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-41
    • (2001) J Clin Invest , vol.108 , pp. 1833-1841
    • Choi, S.J.1    Oba, Y.2    Gazitt, Y.3
  • 58
    • 33751196812 scopus 로고    scopus 로고
    • MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
    • Masih-Khan E, Trudel S, Heise C, et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006;108:3465-71
    • (2006) Blood , vol.108 , pp. 3465-3471
    • Masih-Khan, E.1    Trudel, S.2    Heise, C.3
  • 59
    • 36348988548 scopus 로고    scopus 로고
    • MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
    • Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007;110:3744-52
    • (2007) Blood , vol.110 , pp. 3744-3752
    • Vallet, S.1    Raje, N.2    Ishitsuka, K.3
  • 60
    • 79960269049 scopus 로고    scopus 로고
    • A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
    • Vallet S, Pozzi S, Patel K, et al. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011;25:1174-81
    • (2011) Leukemia , vol.25 , pp. 1174-1181
    • Vallet, S.1    Pozzi, S.2    Patel, K.3
  • 61
    • 84857616177 scopus 로고    scopus 로고
    • Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment
    • D'Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 2012;119:1888-96
    • (2012) Blood , vol.119 , pp. 1888-1896
    • D'Souza, S.1    Kurihara, N.2    Shiozawa, Y.3
  • 62
    • 77955758944 scopus 로고    scopus 로고
    • Novel bone-targeted strategies in oncology
    • Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res 2010;16:4084-93
    • (2010) Clin Cancer Res , vol.16 , pp. 4084-4093
    • Vallet, S.1    Smith, M.R.2    Raje, N.3
  • 63
    • 0035300479 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    • Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
    • (2001) Cancer Res , vol.61 , pp. 3071-3076
    • Hideshima, T.1    Richardson, P.2    Chauhan, D.3
  • 64
    • 0035412366 scopus 로고    scopus 로고
    • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    • Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
    • (2001) Blood , vol.98 , pp. 210-216
    • Davies, F.E.1    Raje, N.2    Hideshima, T.3
  • 66
    • 31544433927 scopus 로고    scopus 로고
    • Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
    • Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91
    • (2006) Cancer Res , vol.66 , pp. 184-191
    • Roccaro, A.M.1    Hideshima, T.2    Raje, N.3
  • 67
    • 51049087523 scopus 로고    scopus 로고
    • Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
    • Munemasa S, Sakai A, Kuroda Y, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008;33:129-36
    • (2008) Int J Oncol , vol.33 , pp. 129-136
    • Munemasa, S.1    Sakai, A.2    Kuroda, Y.3
  • 68
    • 54049156803 scopus 로고    scopus 로고
    • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    • Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925-32
    • (2008) Leukemia , vol.22 , pp. 1925-1932
    • Breitkreutz, I.1    Raab, M.S.2    Vallet, S.3
  • 69
    • 78049386125 scopus 로고    scopus 로고
    • Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
    • Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227-37
    • (2010) Blood , vol.116 , pp. 3227-3237
    • Gorgun, G.1    Calabrese, E.2    Soydan, E.3
  • 70
    • 79953300083 scopus 로고    scopus 로고
    • Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma
    • De Luisi A, Ferrucci A, Coluccia AM, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011;17:1935-46
    • (2011) Clin Cancer Res , vol.17 , pp. 1935-1946
    • De Luisi, A.1    Ferrucci, A.2    Coluccia, A.M.3
  • 71
    • 84894660199 scopus 로고    scopus 로고
    • Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
    • Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2012
    • (2012) Exp Hematol
    • Bolzoni, M.1    Storti, P.2    Bonomini, S.3
  • 72
    • 80855156719 scopus 로고    scopus 로고
    • Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    • Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
    • (2011) Blood , vol.118 , pp. 4771-4779
    • Zhu, Y.X.1    Braggio, E.2    Shi, C.X.3
  • 73
    • 84869082150 scopus 로고    scopus 로고
    • Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
    • Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326-35
    • (2012) Leukemia , vol.26 , pp. 2326-2335
    • Lopez-Girona, A.1    Mendy, D.2    Ito, T.3
  • 74
    • 84877807633 scopus 로고    scopus 로고
    • High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    • Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5):695-700
    • (2013) Br J Haematol , vol.161 , Issue.5 , pp. 695-700
    • Heintel, D.1    Rocci, A.2    Ludwig, H.3
  • 75
    • 84873048466 scopus 로고    scopus 로고
    • High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    • Broyl A, Kuiper R, van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013;121:624-7
    • (2013) Blood , vol.121 , pp. 624-627
    • Broyl, A.1    Kuiper, R.2    Van Duin, M.3
  • 76
    • 77949350034 scopus 로고    scopus 로고
    • Identification of a primary target of thalidomide teratogenicity
    • Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50
    • (2010) Science , vol.327 , pp. 1345-1350
    • Ito, T.1    Ando, H.2    Suzuki, T.3
  • 77
    • 84855224484 scopus 로고    scopus 로고
    • Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
    • Ling SC, Lau EK, Al-Shabeeb A, et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012;97:64-72
    • (2012) Haematologica , vol.97 , pp. 64-72
    • Ling, S.C.1    Lau, E.K.2    Al-Shabeeb, A.3
  • 78
    • 77950542260 scopus 로고    scopus 로고
    • Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
    • McMillin DW, Delmore J, Weisberg E, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010;16:483-9
    • (2010) Nat Med , vol.16 , pp. 483-489
    • McMillin, D.W.1    Delmore, J.2    Weisberg, E.3
  • 79
    • 84859842179 scopus 로고    scopus 로고
    • Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function
    • McMillin DW, Delmore J, Negri JM, et al. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood 2012;119:e131-8
    • (2012) Blood , vol.119
    • McMillin, D.W.1    Delmore, J.2    Negri, J.M.3
  • 80
    • 84879585376 scopus 로고    scopus 로고
    • Niche-based screening identifies novel small molecules that overcome stromal effects in multiple myeloma
    • abstract 571
    • Chattopadhyay S, Stewart AL, Mukherjee S, et al. Niche-based screening identifies novel small molecules that overcome stromal effects in multiple myeloma. Blood 2012;120:abstract 571
    • (2012) Blood , vol.120
    • Chattopadhyay, S.1    Stewart, A.L.2    Mukherjee, S.3
  • 81
    • 0034584607 scopus 로고    scopus 로고
    • The 5TMM series: A useful in vivo mouse model of human multiple myeloma
    • Asosingh K, Radl J, Van Riet I, et al. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000;1:351-6
    • (2000) Hematol J , vol.1 , pp. 351-356
    • Asosingh, K.1    Radl, J.2    Van Riet, I.3
  • 82
    • 34047136169 scopus 로고    scopus 로고
    • The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
    • Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer cell 2007;11:349-60
    • (2007) Cancer Cell , vol.11 , pp. 349-360
    • Carrasco, D.R.1    Sukhdeo, K.2    Protopopova, M.3
  • 83
    • 84864040412 scopus 로고    scopus 로고
    • Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
    • Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120:376-85
    • (2012) Blood , vol.120 , pp. 376-385
    • Chesi, M.1    Matthews, G.M.2    Garbitt, V.M.3
  • 84
    • 0036891888 scopus 로고    scopus 로고
    • Antimyeloma efficacy of thalidomide in the SCID-hu model
    • Yaccoby S, Johnson CL, Mahaffey SC, et al. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002;100:4162-8
    • (2002) Blood , vol.100 , pp. 4162-4168
    • Yaccoby, S.1    Johnson, C.L.2    Mahaffey, S.C.3
  • 85
    • 0142188727 scopus 로고    scopus 로고
    • Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: Biologic and clinical implications
    • Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-96
    • (2003) Cancer Res , vol.63 , pp. 6689-6696
    • Mitsiades, C.S.1    Mitsiades, N.S.2    Bronson, R.T.3
  • 86
    • 79954436115 scopus 로고    scopus 로고
    • A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
    • Calimeri T, Battista E, Conforti F, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11
    • (2011) Leukemia , vol.25 , pp. 707-711
    • Calimeri, T.1    Battista, E.2    Conforti, F.3
  • 87
    • 0242308942 scopus 로고    scopus 로고
    • Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
    • Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-92
    • (2003) J Bone Miner Res , vol.18 , pp. 482-492
    • Croucher, P.I.1    De Hendrik, R.2    Perry, M.J.3
  • 88
    • 33751190044 scopus 로고    scopus 로고
    • Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model
    • Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006;23:291-300
    • (2006) Clin Exp Metastasis , vol.23 , pp. 291-300
    • Menu, E.1    De Leenheer, E.2    De Raeve, H.3
  • 89
    • 84856278440 scopus 로고    scopus 로고
    • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    • Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940-8
    • (2012) Blood , vol.119 , pp. 940-948
    • Neben, K.1    Lokhorst, H.M.2    Jauch, A.3
  • 90
    • 84874768399 scopus 로고    scopus 로고
    • Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan- prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448-55
    • (2013) J Clin Oncol , vol.31 , pp. 448-455
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 91
    • 79955498420 scopus 로고    scopus 로고
    • Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events
    • Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17:2734-43
    • (2011) Clin Cancer Res , vol.17 , pp. 2734-2743
    • Arastu-Kapur, S.1    Anderl, J.L.2    Kraus, M.3
  • 92
    • 79955461011 scopus 로고    scopus 로고
    • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study
    • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40
    • (2011) Lancet Oncol , vol.12 , pp. 431-440
    • Moreau, P.1    Pylypenko, H.2    Grosicki, S.3
  • 93
    • 0141953292 scopus 로고    scopus 로고
    • Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells
    • Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7
    • (2003) Cancer Res , vol.63 , pp. 6174-6177
    • Chauhan, D.1    Li, G.2    Shringarpure, R.3
  • 94
    • 84868156832 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    • Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012;120:3260-70
    • (2012) Blood , vol.120 , pp. 3260-3270
    • Kuhn, D.J.1    Berkova, Z.2    Jones, R.J.3
  • 95
    • 84879293601 scopus 로고    scopus 로고
    • Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model
    • Epub ahead of print
    • Stessman HA, Baughn LB, Sarver A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 2013; Epub ahead of print
    • (2013) Mol Cancer Ther
    • Stessman, H.A.1    Baughn, L.B.2    Sarver, A.3
  • 96
    • 36148944490 scopus 로고    scopus 로고
    • Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
    • Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90
    • (2007) Blood , vol.110 , pp. 3281-3290
    • Kuhn, D.J.1    Chen, Q.2    Voorhees, P.M.3
  • 97
    • 70350708810 scopus 로고    scopus 로고
    • Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
    • Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114:3439-47
    • (2009) Blood , vol.114 , pp. 3439-3447
    • Parlati, F.1    Lee, S.J.2    Aujay, M.3
  • 98
    • 72549116835 scopus 로고    scopus 로고
    • A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
    • O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91
    • (2009) Clin Cancer Res , vol.15 , pp. 7085-7091
    • O'Connor, O.A.1    Stewart, A.K.2    Vallone, M.3
  • 99
    • 84865712581 scopus 로고    scopus 로고
    • A phase i single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
    • Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18:4830-40
    • (2012) Clin Cancer Res , vol.18 , pp. 4830-4840
    • Alsina, M.1    Trudel, S.2    Furman, R.R.3
  • 100
    • 84867295563 scopus 로고    scopus 로고
    • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    • Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-25
    • (2012) Blood , vol.120 , pp. 2817-2825
    • Siegel, D.S.1    Martin, T.2    Wang, M.3
  • 101
    • 84862507585 scopus 로고    scopus 로고
    • An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    • Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119:5661-70
    • (2012) Blood , vol.119 , pp. 5661-5670
    • Vij, R.1    Wang, M.2    Kaufman, J.L.3
  • 102
    • 84865333050 scopus 로고    scopus 로고
    • A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    • Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-9
    • (2012) Blood , vol.120 , pp. 1801-1809
    • Jakubowiak, A.J.1    Dytfeld, D.2    Griffith, K.A.3
  • 103
    • 84879578512 scopus 로고    scopus 로고
    • Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate
    • abstract 333
    • Sonneveld P, Asselbergs E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate. Blood 2012;120:abstract 333
    • (2012) Blood , vol.120
    • Sonneveld, P.1    Asselbergs, E.2    Zweegman, S.3
  • 104
    • 84879569480 scopus 로고    scopus 로고
    • Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma
    • abstract 445
    • Mikhael J, Reeder C, Libby E, et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. Blood 2012;120:abstract 445
    • (2012) Blood , vol.120
    • Mikhael, J.1    Reeder, C.2    Libby, E.3
  • 105
    • 65649139708 scopus 로고    scopus 로고
    • Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)
    • Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52:3028-38
    • (2009) J Med Chem , vol.52 , pp. 3028-3038
    • Zhou, H.J.1    Aujay, M.A.2    Bennett, M.K.3
  • 106
    • 78649755360 scopus 로고    scopus 로고
    • A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
    • Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010;116:4906-15
    • (2010) Blood , vol.116 , pp. 4906-4915
    • Chauhan, D.1    Singh, A.V.2    Aujay, M.3
  • 107
    • 41949110089 scopus 로고    scopus 로고
    • CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
    • Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111:2765-75
    • (2008) Blood , vol.111 , pp. 2765-2775
    • Piva, R.1    Ruggeri, B.2    Williams, M.3
  • 108
    • 39749143840 scopus 로고    scopus 로고
    • Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer
    • Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51:1068-72
    • (2008) J Med Chem , vol.51 , pp. 1068-1072
    • Dorsey, B.D.1    Iqbal, M.2    Chatterjee, S.3
  • 109
    • 84872109533 scopus 로고    scopus 로고
    • A first in human phase i study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
    • Gallerani E, Zucchetti M, Brunelli D, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2013;49:290-6
    • (2013) Eur J Cancer , vol.49 , pp. 290-296
    • Gallerani, E.1    Zucchetti, M.2    Brunelli, D.3
  • 110
    • 80051691845 scopus 로고    scopus 로고
    • In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
    • Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011;17:5311-21
    • (2011) Clin Cancer Res , vol.17 , pp. 5311-5321
    • Chauhan, D.1    Tian, Z.2    Zhou, B.3
  • 111
    • 84879562212 scopus 로고    scopus 로고
    • A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)
    • abstract 332
    • Kumar SK, Berdeja JG, Niesvizky R, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Blood 2012;120:abstract 332
    • (2012) Blood , vol.120
    • Kumar, S.K.1    Berdeja, J.G.2    Niesvizky, R.3
  • 112
    • 27644562277 scopus 로고    scopus 로고
    • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    • Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19
    • (2005) Cancer Cell , vol.8 , pp. 407-419
    • Chauhan, D.1    Catley, L.2    Li, G.3
  • 113
    • 38949125853 scopus 로고    scopus 로고
    • Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
    • Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111:1654-64
    • (2008) Blood , vol.111 , pp. 1654-1664
    • Chauhan, D.1    Singh, A.2    Brahmandam, M.3
  • 114
    • 84857919694 scopus 로고    scopus 로고
    • Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052) a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM)
    • abstract 302
    • Richardson PG, Spencer A, Cannell P, et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood 2011;118:abstract 302
    • (2011) Blood , vol.118
    • Richardson, P.G.1    Spencer, A.2    Cannell, P.3
  • 115
    • 78650348146 scopus 로고    scopus 로고
    • PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
    • Singh AV, Bandi M, Aujay MA, et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011;152:155-63
    • (2011) Br J Haematol , vol.152 , pp. 155-163
    • Singh, A.V.1    Bandi, M.2    Aujay, M.A.3
  • 116
    • 84866021069 scopus 로고    scopus 로고
    • A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance
    • Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22:345-58
    • (2012) Cancer Cell , vol.22 , pp. 345-358
    • Chauhan, D.1    Tian, Z.2    Nicholson, B.3
  • 117
    • 84860744403 scopus 로고    scopus 로고
    • Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    • Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69
    • (2012) N Engl J Med , vol.366 , pp. 1759-1769
    • Palumbo, A.1    Hajek, R.2    Delforge, M.3
  • 118
    • 84858858229 scopus 로고    scopus 로고
    • A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    • Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-7
    • (2012) Blood , vol.119 , pp. 2764-2767
    • Dimopoulos, M.A.1    Richardson, P.G.2    Brandenburg, N.3
  • 119
    • 84857922830 scopus 로고    scopus 로고
    • Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results
    • abstract 634
    • Richardson PG, Siegel DS, Vij R, et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. Blood 2011;118:abstract 634
    • (2011) Blood , vol.118
    • Richardson, P.G.1    Siegel, D.S.2    Vij, R.3
  • 120
    • 84877605245 scopus 로고    scopus 로고
    • Phase i study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
    • Richardson PG, Siegel D, Baz R, et al. Phase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121(11):1961-7
    • (2013) Blood , vol.121 , Issue.11 , pp. 1961-1967
    • Richardson, P.G.1    Siegel, D.2    Baz, R.3
  • 121
    • 80052937408 scopus 로고    scopus 로고
    • Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease
    • Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970-5
    • (2011) Blood , vol.118 , pp. 2970-2975
    • Lacy, M.Q.1    Allred, J.B.2    Gertz, M.A.3
  • 122
    • 84877622448 scopus 로고    scopus 로고
    • Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02
    • Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood 2013
    • (2013) Blood
    • Leleu, X.1    Attal, M.2    Arnulf, B.3
  • 123
    • 84874908368 scopus 로고    scopus 로고
    • Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label study
    • abstract LBA-6
    • Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood 2012;120:abstract LBA-6
    • (2012) Blood , vol.120
    • Dimopoulos, M.A.1    Lacy, M.Q.2    Moreau, P.3
  • 124
    • 84877147624 scopus 로고    scopus 로고
    • Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma
    • abstract 446
    • Palumbo A, Larocca A, Montefusco V, et al. Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma. Blood 2012;120:abstract 446
    • (2012) Blood , vol.120
    • Palumbo, A.1    Larocca, A.2    Montefusco, V.3
  • 125
    • 84877136004 scopus 로고    scopus 로고
    • ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma
    • abstract 77
    • Mark TM, Boyer A, Rossi AC, et al. ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood 2012;120:abstract 77
    • (2012) Blood , vol.120
    • Mark, T.M.1    Boyer, A.2    Rossi, A.C.3
  • 126
    • 0034905327 scopus 로고    scopus 로고
    • 2B4 (CD244) and CS1: Novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes
    • Boles KS, Stepp SE, Bennett M, et al. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 2001;181:234-49
    • (2001) Immunol Rev , vol.181 , pp. 234-249
    • Boles, K.S.1    Stepp, S.E.2    Bennett, M.3
  • 127
    • 51649083849 scopus 로고    scopus 로고
    • Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
    • Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37
    • (2008) Blood , vol.112 , pp. 1329-1337
    • Tai, Y.T.1    Dillon, M.2    Song, W.3
  • 128
    • 52049104695 scopus 로고    scopus 로고
    • CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    • Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-84
    • (2008) Clin Cancer Res , vol.14 , pp. 2775-2784
    • Hsi, E.D.1    Steinle, R.2    Balasa, B.3
  • 129
    • 70349481310 scopus 로고    scopus 로고
    • Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    • van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-24
    • (2009) Mol Cancer Ther , vol.8 , pp. 2616-2624
    • Van Rhee, F.1    Szmania, S.M.2    Dillon, M.3
  • 130
    • 66149133630 scopus 로고    scopus 로고
    • CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
    • Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009;113:4309-18
    • (2009) Blood , vol.113 , pp. 4309-4318
    • Tai, Y.T.1    Soydan, E.2    Song, W.3
  • 131
    • 84864118302 scopus 로고    scopus 로고
    • A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    • Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552-9
    • (2012) Blood , vol.120 , pp. 552-559
    • Zonder, J.A.1    Mohrbacher, A.F.2    Singhal, S.3
  • 132
    • 84862672400 scopus 로고    scopus 로고
    • Phase i trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma
    • Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;30:1960-5
    • (2012) J Clin Oncol , vol.30 , pp. 1960-1965
    • Jakubowiak, A.J.1    Benson, D.M.2    Bensinger, W.3
  • 133
    • 84879565775 scopus 로고    scopus 로고
    • A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): Updated results
    • abstract 202
    • Richardson P, Jagannath S, Moreau P, et al. A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results. Blood 2012;120:abstract 202
    • (2012) Blood , vol.120
    • Richardson, P.1    Jagannath, S.2    Moreau, P.3
  • 134
    • 79251581902 scopus 로고    scopus 로고
    • Towards effective immunotherapy of myeloma: Enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
    • van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96:284-90
    • (2011) Haematologica , vol.96 , pp. 284-290
    • Van Der Veer, M.S.1    De Weers, M.2    Van Kessel, B.3
  • 135
    • 79251570884 scopus 로고    scopus 로고
    • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
    • de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8
    • (2011) J Immunol , vol.186 , pp. 1840-1848
    • De Weers, M.1    Tai, Y.T.2    Van Der Veer, M.S.3
  • 136
    • 84878159958 scopus 로고    scopus 로고
    • Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study
    • abstract 73
    • Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. Blood 2012;120:abstract 73
    • (2012) Blood , vol.120
    • Plesner, T.1    Lokhorst, H.2    Gimsing, P.3
  • 137
    • 77952315198 scopus 로고    scopus 로고
    • A phase i multidose study of dacetuzumab (SGN-40; Humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
    • Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010;95:845-8
    • (2010) Haematologica , vol.95 , pp. 845-848
    • Hussein, M.1    Berenson, J.R.2    Niesvizky, R.3
  • 138
    • 84866314973 scopus 로고    scopus 로고
    • A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
    • Bensinger W, Maziarz RT, Jagannath S, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012;159:58-66
    • (2012) Br J Haematol , vol.159 , pp. 58-66
    • Bensinger, W.1    Maziarz, R.T.2    Jagannath, S.3
  • 139
    • 67449119398 scopus 로고    scopus 로고
    • The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
    • Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37
    • (2009) Clin Cancer Res , vol.15 , pp. 4028-4037
    • Ikeda, H.1    Hideshima, T.2    Fulciniti, M.3
  • 140
    • 84879588054 scopus 로고    scopus 로고
    • BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: Safety and further evidence of clinical activity
    • abstract 4042
    • Heffner LT, Jagannath S, Zimmerman TM, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood 2012;120:abstract 4042
    • (2012) Blood , vol.120
    • Heffner, L.T.1    Jagannath, S.2    Zimmerman, T.M.3
  • 141
    • 84872087150 scopus 로고    scopus 로고
    • Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
    • Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013;98:79-86
    • (2013) Haematologica , vol.98 , pp. 79-86
    • Pessoa De Magalhaes, R.J.1    Vidriales, M.B.2    Paiva, B.3
  • 142
    • 78751510278 scopus 로고    scopus 로고
    • Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    • Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117:393-402
    • (2011) Blood , vol.117 , pp. 393-402
    • Rosenblatt, J.1    Vasir, B.2    Uhl, L.3
  • 143
    • 84879559198 scopus 로고    scopus 로고
    • Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation
    • abstract 578
    • Rosenblatt J, Avivi I, Vasir B, et al. Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation. Blood 2012;120:abstract 578
    • (2012) Blood , vol.120
    • Rosenblatt, J.1    Avivi, I.2    Vasir, B.3
  • 144
    • 84866156002 scopus 로고    scopus 로고
    • CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis
    • Brown R, Kabani K, Favaloro J, et al. CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood 2012;120:2055-63
    • (2012) Blood , vol.120 , pp. 2055-2063
    • Brown, R.1    Kabani, K.2    Favaloro, J.3
  • 145
    • 68949212379 scopus 로고    scopus 로고
    • Lysine acetylation targets protein complexes and co-regulates major cellular functions
    • Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834-40
    • (2009) Science , vol.325 , pp. 834-840
    • Choudhary, C.1    Kumar, C.2    Gnad, F.3
  • 146
    • 0141593496 scopus 로고    scopus 로고
    • NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    • Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22
    • (2003) Blood , vol.102 , pp. 2615-2622
    • Catley, L.1    Weisberg, E.2    Tai, Y.T.3
  • 147
    • 39749103428 scopus 로고    scopus 로고
    • Phase i trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    • Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49:502-7
    • (2008) Leuk Lymphoma , vol.49 , pp. 502-507
    • Richardson, P.1    Mitsiades, C.2    Colson, K.3
  • 148
    • 69349097803 scopus 로고    scopus 로고
    • Phase i study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
    • Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-7
    • (2009) Clin Cancer Res , vol.15 , pp. 5250-5257
    • Badros, A.1    Burger, A.M.2    Philip, S.3
  • 149
    • 84867422068 scopus 로고    scopus 로고
    • Phase i trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma
    • Weber DM, Graef T, Hussein M, et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12:319-24
    • (2012) Clin Lymphoma Myeloma Leuk , vol.12 , pp. 319-324
    • Weber, D.M.1    Graef, T.2    Hussein, M.3
  • 150
    • 84859719940 scopus 로고    scopus 로고
    • Vantage 088: Vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: Results of a global, randomized phase 3 trial
    • abstract 811
    • Dimopoulos M, Jagannath S, Yoon S, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. Blood 2011;118:abstract 811
    • (2011) Blood , vol.118
    • Dimopoulos, M.1    Jagannath, S.2    Yoon, S.3
  • 151
    • 84876434224 scopus 로고    scopus 로고
    • Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Results of a phase 1 study
    • abstract 336
    • Kaufman JL, Shah JJ, Laubach JP, et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): results of a phase 1 study. Blood 2012;120:abstract 336
    • (2012) Blood , vol.120
    • Kaufman, J.L.1    Shah, J.J.2    Laubach, J.P.3
  • 152
    • 84862895569 scopus 로고    scopus 로고
    • Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
    • Offidani M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012;53:1722-7
    • (2012) Leuk Lymphoma , vol.53 , pp. 1722-1727
    • Offidani, M.1    Polloni, C.2    Cavallo, F.3
  • 153
    • 33645737411 scopus 로고    scopus 로고
    • Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
    • Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81
    • (2006) Cancer Res , vol.66 , pp. 3773-3781
    • Nawrocki, S.T.1    Carew, J.S.2    Pino, M.S.3
  • 154
    • 67349241955 scopus 로고    scopus 로고
    • DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
    • Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873-86
    • (2009) Cell , vol.137 , pp. 873-886
    • Peterson, T.R.1    Laplante, M.2    Thoreen, C.C.3
  • 155
    • 10244229652 scopus 로고    scopus 로고
    • In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
    • Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104:4181-7
    • (2004) Blood , vol.104 , pp. 4181-4187
    • Frost, P.1    Moatamed, F.2    Hoang, B.3
  • 156
    • 67650995912 scopus 로고    scopus 로고
    • Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    • McMillin DW, Ooi M, Delmore J, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009;69:5835-42
    • (2009) Cancer Res , vol.69 , pp. 5835-5842
    • McMillin, D.W.1    Ooi, M.2    Delmore, J.3
  • 157
    • 77950788603 scopus 로고    scopus 로고
    • Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma
    • Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9:963-75
    • (2010) Mol Cancer Ther , vol.9 , pp. 963-975
    • Cirstea, D.1    Hideshima, T.2    Rodig, S.3
  • 158
    • 81155151824 scopus 로고    scopus 로고
    • Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial
    • Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011;29:4243-9
    • (2011) J Clin Oncol , vol.29 , pp. 4243-4249
    • Richardson, P.G.1    Wolf, J.2    Jakubowiak, A.3
  • 159
    • 84864322405 scopus 로고    scopus 로고
    • Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: A Phase i Multiple Myeloma Research Consortium study
    • Jakubowiak AJ, Richardson PG, Zimmerman T, et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 2012;158:472-80
    • (2012) Br J Haematol , vol.158 , pp. 472-480
    • Jakubowiak, A.J.1    Richardson, P.G.2    Zimmerman, T.3
  • 160
    • 68649117850 scopus 로고    scopus 로고
    • Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
    • Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in
    • (2009) Leuk Res , vol.33 , pp. 1475-1480
    • Farag, S.S.1    Zhang, S.2    Jansak, B.S.3
  • 161
    • 79952042047 scopus 로고    scopus 로고
    • Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: A multicentre, phase 1/2, open-label, dose-escalation study
    • Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011;12:263-72
    • (2011) Lancet Oncol , vol.12 , pp. 263-272
    • Ghobrial, I.M.1    Weller, E.2    Vij, R.3
  • 162
    • 84871806385 scopus 로고    scopus 로고
    • Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
    • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
    • (2013) J Clin Oncol , vol.31 , pp. 88-94
    • Advani, R.H.1    Buggy, J.J.2    Sharman, J.P.3
  • 163
    • 84865585752 scopus 로고    scopus 로고
    • Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
    • Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012;120:1877-87
    • (2012) Blood , vol.120 , pp. 1877-1887
    • Tai, Y.T.1    Chang, B.Y.2    Kong, S.Y.3
  • 164
    • 84862524640 scopus 로고    scopus 로고
    • Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial
    • Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012;119:5374-83
    • (2012) Blood , vol.119 , pp. 5374-5383
    • Morgan, G.J.1    Davies, F.E.2    Gregory, W.M.3
  • 165
    • 77950438331 scopus 로고    scopus 로고
    • Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
    • Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010;107:5124-9
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 5124-5129
    • Vallet, S.1    Mukherjee, S.2    Vaghela, N.3
  • 166
    • 77956555237 scopus 로고    scopus 로고
    • ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: Preliminary analysis
    • abstract 749
    • Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis. Blood 2009;114:abstract 749
    • (2009) Blood , vol.114
    • Abdulkadyrov, K.M.1    Salogub, G.N.2    Khuazheva, N.K.3
  • 167
    • 84881475207 scopus 로고    scopus 로고
    • Lenalidomide in combination with an activin A neutralizing antibody; Preclinical rationale for a novel anti-myeloma strategy
    • Scullen T, Santo L, Vallet S, et al. Lenalidomide in combination with an activin A neutralizing antibody; preclinical rationale for a novel anti-myeloma strategy. Leukemia 2013
    • (2013) Leukemia
    • Scullen, T.1    Santo, L.2    Vallet, S.3
  • 168
    • 84879563393 scopus 로고    scopus 로고
    • Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: Results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression
    • abstract 331
    • Munshi NC, Abonour R, Beck JT, et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood 2012;120:abstract 331
    • (2012) Blood , vol.120
    • Munshi, N.C.1    Abonour, R.2    Beck, J.T.3
  • 169
    • 84876452938 scopus 로고    scopus 로고
    • PANORAMA 2: Panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
    • abstract 1852
    • Richardson P, Alsina M, Weber D, et al. PANORAMA 2: panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood 2012;218:abstract 1852
    • (2012) Blood , vol.218
    • Richardson, P.1    Alsina, M.2    Weber, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.